Literature DB >> 15009724

Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals.

Marcin Kortylewski1, Waraporn Komyod, Maria-Elisabeth Kauffmann, Anja Bosserhoff, Peter C Heinrich, Iris Behrmann.   

Abstract

Interferon-gamma, a known inhibitor of tumor cell growth, has been used in several protocols for the treatment of melanoma. We have studied the molecular events underlying interferon-gamma-induced G0/G1 arrest in four metastatic melanoma cell lines with different responsiveness to interferon-gamma. The growth arrest did not result from enhanced expression of cyclin-dependent kinase inhibitors p21 and p27. Instead, it correlated with downregulation of cyclin E and cyclin A and inhibition of their associated kinase activities. We show that interferon-gamma-induced growth inhibition could be abrogated by overexpression of dominant negative STAT1 (signal transducer and activator of transcription 1) in the melanoma cell line A375, suggesting that STAT1 plays a crucial part for the anti-proliferative effect. Erythropoietin stimulation of a chimeric receptor led to a concentration-dependent STAT1 activation and concomitant growth arrest when it contained the STAT recruitment motif Y440 of the interferon-gamma receptor 1. In contrast, dose-response studies for interferon-gamma revealed a discrepancy between levels of STAT1 activation and the extent of growth inhibition; whereas STAT1 was activated by low doses of interferon-gamma (10 U per mL), growth inhibitory effects were only visible with 100-fold higher concentrations. Our results suggest the presence of additional signals emanating from the interferon-gamma receptor, which may counteract the anti-proliferative function of STAT1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009724     DOI: 10.1046/j.0022-202X.2004.22237.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

2.  Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression.

Authors:  Filiberto Cedeno-Laurent; Matthew Opperman; Steven R Barthel; Vijay K Kuchroo; Charles J Dimitroff
Journal:  J Immunol       Date:  2012-02-17       Impact factor: 5.422

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

Review 4.  IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression.

Authors:  Hussein F Aqbi; Matthew Wallace; Samay Sappal; Kyle K Payne; Masoud H Manjili
Journal:  J Leukoc Biol       Date:  2018-02-22       Impact factor: 4.962

5.  Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.

Authors:  Toshihiro Nagato; Young-Ran Lee; Yasuaki Harabuchi; Esteban Celis
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

6.  Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.

Authors:  Filiberto Cedeno-Laurent; Matthew J Opperman; Steven R Barthel; Danielle Hays; Tobias Schatton; Qian Zhan; Xiaoying He; Khushi L Matta; Jeffrey G Supko; Markus H Frank; George F Murphy; Charles J Dimitroff
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

Review 7.  Multiple drug resistance mechanisms in cancer.

Authors:  Bruce C Baguley
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

8.  Mechanisms of resistance to interferon-gamma-mediated cell growth arrest in human oral squamous carcinoma cells.

Authors:  Miki Hiroi; Kazumasa Mori; Keisuke Sekine; Yoshiichi Sakaeda; Jun Shimada; Yoshihiro Ohmori
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

9.  Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.

Authors:  Yao Chen; Yusen Zhou; Suimin Qiu; Kaijuan Wang; Siwei Liu; Xuan-Xian Peng; Junfeng Li; Eng M Tan; Jian-Ying Zhang
Journal:  Cancer Lett       Date:  2009-08-15       Impact factor: 8.679

Review 10.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.